RXRX - Company ID 0001601830
The table below shows RECURSION PHARMACEUTICALS, INC.'s balance sheet line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & equivalents | $743.29M | $594.35M | $391.56M | $549.91M | $285.12M |
| Short-term investments | - | - | - | $0.00 | $231.45M |
| Receivables | - | - | - | $0.00 | $34.00K |
| Inventory | - | - | - | - | - |
| Total current assets | $812.85M | $714.27M | $438.14M | $569.81M | $534.72M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Property, plant & equipment | $103.93M | $141.06M | $86.51M | $88.19M | $64.72M |
| Goodwill | $162.16M | $148.87M | $52.06M | $801.00K | $801.00K |
| Total assets | $1.47B | $1.45B | $653.70M | $701.29M | $610.35M |
| Accounts payable | $18.12M | $21.61M | $3.95M | $4.59M | $2.82M |
| Total current liabilities | $147.71M | $187.47M | $93.17M | $100.27M | $46.66M |
| Long-term debt | - | - | - | - | $723.00K |
| Total liabilities | $343.26M | $413.82M | $190.26M | $215.48M | $67.41M |
| Retained earnings | -$2.08B | -$1.43B | -$967.62M | -$639.56M | -$400.08M |
| Total equity | $1.13B | $1.03B | $463.44M | $485.81M | $542.94M |